Related Experiment Video
Updated: May 31, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the
Caroline Medi1, Jonathan M Kalman, Steven J Spence
1Department of Cardiology, Alfred Hospital and Baker IDI, Melbourne, Australia.
Insights
Hypertension (HT) causes atrial remodeling, including slower conduction and increased risk of atrial fibrillation (AF). These findings highlight how chronic HT impacts heart electrical activity and AF susceptibility.
Area of Science:
- Cardiology
- Electrophysiology
- Cardiac Remodeling
Background:
- Hypertension (HT) is a major risk factor for atrial fibrillation (AF).
- The specific effects of chronic HT on the atria in humans are not well understood.
- This study investigates atrial changes in patients with HT and left ventricular hypertrophy (LVH).
Purpose of the Study:
- To characterize the electrophysiologic (EP) and electroanatomic (EA) remodeling of the right atrium (RA) in patients with chronically treated systemic HT and LVH.
- To assess the impact of HT on atrial conduction and electrical properties.
Main Methods:
- Compared 20 patients with systemic HT and LVH to controls without HT.
- Utilized conventional EP and EA mapping, including voltage and activation mapping.
- Measured RA refractoriness, conduction velocities, activation times, and voltages at various cycle lengths.
Main Results:
- Patients with HT showed significantly slower global and regional RA conduction velocities.
- Increased areas of low voltage (<0.5 mV) were observed in the RA of HT patients.
- Sustained atrial fibrillation (AF) was induced in 30% of HT patients, compared to none in controls.
Conclusions:
- Chronic systemic HT with LVH leads to significant atrial remodeling.
- This remodeling includes global and regional conduction slowing and increased AF inducibility.
- These electrophysiologic changes likely contribute to the heightened risk of AF in hypertensive individuals.
Introduction:
Hypertension (HT) is the most common modifiable risk factor for atrial fibrillation (AF), yet little is known of the atrial effects of chronic HT in humans. We aimed to characterize the electrophysiologic (EP) and electroanatomic (EA) remodeling of the right atrium (RA) in patients with chronically treated systemic HT and left ventricular hypertrophy (LVH) without a history of AF.
Methods And Results:
Twenty patients with (systolic BP 145 ± 10 mmHg) and without (BP 119 ± 11 mmHg, P < 0.01) systemic HT underwent detailed conventional EP and EA voltage and activation mapping. We measured RA refractoriness at the coronary sinus and high septum at cycle lengths (CLs) 600 and 450 ms, and RA conduction velocities, activation times, and voltages at a global and regional level at CLs 600 ms and 300 ms. HT was associated with slowing of global (73 ± 17 cm/s vs 96 ± 12 cm/s in controls, P < 0.01) and regional conduction velocity particularly in the posterior RA (70 ± 17 cm/s vs 96 ± 12 cm/s in controls, P < 0.01) at the crista terminalis (fractionation and double potentials in HT 72%± 4 vs 43%± 23 in controls, P = 0.04). Mean RA voltage was similar between the 2 groups, however HT was associated with an increase in areas of low voltage (<0.5 mV; HT 13% vs controls 9%, P = 0.04). Sustained AF was induced in 30% HT patients and no controls.
Conclusion:
Chronically treated systemic HT with LVH is accompanied by atrial remodeling characterized by: (i) global conduction slowing, (ii) regional conduction delay particularly at the crista terminalis, and (iii) increased AF inducibility. These changes may in part be responsible for the increased propensity to AF associated with systemic HT.
Related Concept Videos
Heart Failure II: Pathophysiology
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Hypertension III: Clinical Manifestations and Diagnostic Studies
Pathophysiology of Heart Failure
Hypertension II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy

